Rejuvenate Biomed has completed enrollment in a Phase 2 trial of RJx-01, a multi-pathway therapeutic targeting mitochondrial dysfunction and neuromuscular impairment in COPD-related sarcopenia. The drug showed improvements in muscle strength and fatigue resistance in prior Phase 1b data, with topline results expected by end of 2026.
Key Points
- RJx-01 targets mitochondrial dysfunction, inflammation, fibrosis, and neuromuscular impairment
- Phase 1b data demonstrated gains in muscle strength, function, and fatigue resistance
- Addresses unmet need: no current approved pharmacologic treatments for COPD-induced sarcopenia
Longevity Analysis
COPD-induced muscle loss represents a critical convergence point where respiratory limitation, energy production deficiency, and structural decline accelerate age-related deterioration. A therapeutic that addresses mitochondrial function directly—rather than treating symptoms downstream—targets a root mechanism by which respiratory compromise cascades into systemic weakness. Success in this population would establish a model for treating sarcopenia in conditions where multiple systems are simultaneously compromised, rather than waiting for late-stage functional loss to become irreversible.
Original published by LT Wire.